vanoxerine has been researched along with Auricular Flutter in 4 studies
vanoxerine: structure given in first source
vanoxerine : An N-alkylpiperazine that consists of piperazine bearing 2-bis(4-fluorophenyl)methoxy]ethyl and 3-phenylpropyl groups at positions 1 and 4 respectively. Potent, competitive inhibitor of dopamine uptake (Ki = 1 nM for inhibition of striatal dopamine uptake). Has > 100-fold lower affinity for the noradrenalin and 5-HT uptake carriers. Also a potent sigma ligand (IC50 = 48 nM). Centrally active following systemic administration.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Vanoxerine is an oral, 1,4-dialkylpiperazine derivative antiarrhythmic drug being evaluated for pharmacological cardioversion of atrial fibrillation (AF)." | 9.22 | Randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of a single oral dose of vanoxerine for the conversion of subjects with recent onset atrial fibrillation or flutter to normal sinus rhythm: RESTORE SR. ( Camm, AJ; Cotter, G; Davison, BA; Dittrich, HC; Feld, G; Iwashita, J; Koch, G; Kowey, PR; Piccini, JP; Pritchett, EL; van Gelder, IC; Waldo, A; Wiener, LE, 2016) |
| "Vanoxerine is an oral, 1,4-dialkylpiperazine derivative antiarrhythmic drug being evaluated for pharmacological cardioversion of atrial fibrillation (AF)." | 5.22 | Randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of a single oral dose of vanoxerine for the conversion of subjects with recent onset atrial fibrillation or flutter to normal sinus rhythm: RESTORE SR. ( Camm, AJ; Cotter, G; Davison, BA; Dittrich, HC; Feld, G; Iwashita, J; Koch, G; Kowey, PR; Piccini, JP; Pritchett, EL; van Gelder, IC; Waldo, A; Wiener, LE, 2016) |
| "Vanoxerine is a promising, new, investigational antiarrhythmic drug." | 1.37 | Oral vanoxerine prevents reinduction of atrial tachyarrhythmias: preliminary results. ( Brown, AM; Cakulev, I; Khrestian, CM; Lacerda, AE; Ryu, K; Waldo, AL, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dittrich, HC | 2 |
| Feld, GK | 1 |
| Bahnson, TD | 1 |
| Camm, AJ | 2 |
| Golitsyn, S | 1 |
| Katz, A | 1 |
| Koontz, JI | 1 |
| Kowey, PR | 2 |
| Waldo, AL | 3 |
| Brown, AM | 3 |
| Piccini, JP | 1 |
| Pritchett, EL | 1 |
| Davison, BA | 1 |
| Cotter, G | 1 |
| Wiener, LE | 1 |
| Koch, G | 1 |
| Feld, G | 1 |
| Waldo, A | 1 |
| van Gelder, IC | 1 |
| Iwashita, J | 1 |
| Matsumoto, N | 1 |
| Khrestian, CM | 2 |
| Ryu, K | 2 |
| Lacerda, AE | 2 |
| Cakulev, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized, Double-blind, Placebo-controlled Dose Modification Study to Evaluate the Safety and Efficacy of Single Doses of Vanoxerine for Conversion of Subjects With Recent Onset Atrial Fibrillation or Flutter to Normal Sinus Rhythm[NCT01691313] | Phase 2 | 104 participants (Actual) | Interventional | 2012-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
proportion of subjects who convert to sinus rhythm through 24 hours after start of study drug (NCT01691313)
Timeframe: baseline through 24 hours
| Intervention | participants (Number) |
|---|---|
| Placebo | 10 |
| Vanoxerine 200mg | 13 |
| Vanoxerine 300mg | 16 |
| Vanoxerine 400mg | 21 |
proportion of subjects who convert to sinus rhythm through 4 hours after start of study drug (NCT01691313)
Timeframe: baseline through 4 hours
| Intervention | participants (Number) |
|---|---|
| Placebo | 4 |
| Vanoxerine 200mg | 4 |
| Vanoxerine 300mg | 11 |
| Vanoxerine 400mg | 13 |
2 trials available for vanoxerine and Auricular Flutter
| Article | Year |
|---|---|
COR-ART: A multicenter, randomized, double-blind, placebo-controlled dose-ranging study to evaluate single oral doses of vanoxerine for conversion of recent-onset atrial fibrillation or flutter to normal sinus rhythm.
Topics: Administration, Oral; Aged; Atrial Fibrillation; Atrial Flutter; Dopamine Uptake Inhibitors; Double- | 2015 |
Randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of a single oral dose of vanoxerine for the conversion of subjects with recent onset atrial fibrillation or flutter to normal sinus rhythm: RESTORE SR.
Topics: Administration, Oral; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Double-Blin | 2016 |
2 other studies available for vanoxerine and Auricular Flutter
| Article | Year |
|---|---|
Vanoxerine, a new drug for terminating atrial fibrillation and flutter.
Topics: Animals; Anti-Asthmatic Agents; Atrial Fibrillation; Atrial Flutter; Dogs; Electrocardiography; Hear | 2010 |
Oral vanoxerine prevents reinduction of atrial tachyarrhythmias: preliminary results.
Topics: Administration, Oral; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cardiac | 2011 |